<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72432">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162758</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-P4-003</org_study_id>
    <secondary_id>U1111-1152-6767</secondary_id>
    <nct_id>NCT02162758</nct_id>
  </id_info>
  <brief_title>Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation</brief_title>
  <official_title>A Randomized, Double-Blind, Phase 4 Study to Evaluate the Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of dexlansoprazole QD and BID dosing on the
      recurrence of intestinal metaplasia (IM) in subjects who achieved complete eradication of
      Barrett's esophagus (BE) with high-grade dysplasia (HGD) following radiofrequency ablation
      (RFA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called dexlansoprazole. The purpose of this study is
      to evaluate the effect of 12 months of treatment with dexlansoprazole 60 mg QD or
      dexlansoprazole 60 mg BID on the recurrence of IM in participants who have achieved complete
      eradication of intestinal metaplasia (CEIM) and dysplasia (CED) with Radiofrequency Ablation
      (RFA). The study will enroll approximately 150 patients. Participants will be randomly
      assigned (by chance, like flipping a coin) to one of the two treatment groups which will
      remain undisclosed to the patient and study doctor during the study (unless there is an
      urgent medical need):

        -  Dexlansoprazole 60 mg once a day and placebo (this is a capsule that looks like the
           study drug but has no active ingredient) once a day

        -  Dexlansoprazole 60 mg twice a day. All participants will be asked to take one capsule
           twice a day at the same time each day throughout the study.

      This randomized, double-blind, multi-center, parallel group trial will be conducted in North
      America. The overall time to participate in this study is up to 13 months. Participants will
      make 5 visits to the clinic, and will undergo a safety follow-up assessment 30 days after
      the last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decisions; No Safety Concerns
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Recurrence of Intestinal Metaplasia (IM) at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Recurrence of IM will be assessed by endoscopic esophageal biopsy, read by the local site's pathology laboratory and sent to a central pathology laboratory for standardized processing and interpretation using standardized criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Recurrence of Intestinal Metaplasia (IM) with Dysplasia at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Recurrence of IM with dysplasia will be assessed by endoscopic esophageal biopsy, read by the local site's pathology laboratory and sent to a central pathology laboratory for standardized processing and interpretation using standardized criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants demonstrating Erosive Esophagitis (EE) during the 12 month treatment phase of the study.</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Endoscopic observation and Grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in quality of life (GERD-HRQL) at 12 months</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Quality of life will be assessed using a Quality of Life Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Dexlansoprazole 60 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexlansoprazole 60 mg, delayed-release capsules, orally, once daily (QD) and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexlansoprazole 120 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexlansoprazole 60 mg, delayed-release capsules, orally, twice daily (BID) for up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole</intervention_name>
    <description>Dexlansoprazole delayed-release capsules</description>
    <arm_group_label>Dexlansoprazole 60 mg QD</arm_group_label>
    <arm_group_label>Dexlansoprazole 120 mg BID</arm_group_label>
    <other_name>Dexilant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole Placebo</intervention_name>
    <description>Dexlansoprazole placebo-matching capsules</description>
    <arm_group_label>Dexlansoprazole 60 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is male or female and aged 18 to 80 years, inclusive.

          2. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          3. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          4. Has a history of initial complete eradication of intestinal metaplasia (CEIM)
             following radiofrequency ablation (RFA) for Barrett's esophagus with high-grade
             dysplasia within the past 3 years.

          5. Had attained CEIM within 12 months of receiving his or her first RFA treatment.

          6. Has endoscopic and histologic confirmed evidence of CEIM prior to randomization.

          7. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          8. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from
             signing of informed consent throughout the duration of the study.

        Exclusion Criteria:

          -  1. Has evidence of cardiovascular, pulmonary, central nervous system, hepatic,
             hematopoietic, renal, metabolic, endocrine or gastrointestinal disease, or serious
             allergy, asthma, or allergic skin rash that suggests clinically significant,
             uncontrolled underlying disease or condition (other than the disease being studied),
             which may impact the ability of the participant to participate or potentially
             confound the study results.

             2. Had previous ablative therapy with a modality other than RFA for Barrett's
             esophagus (photodynamic therapy, multipolar electrical coagulation, argon plasma
             coagulation, or laser treatment) with the exception of up to 3 treatments of
             thermal/coagulation therapy for focal residual disease following otherwise successful
             RFA therapy.

             3. Has a co-existing disease affecting the esophagus (eg, erosive esophagitis,
             esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture),
             history of radiation therapy or cryotherapy to the esophagus, caustic or
             physiochemical trauma such as sclerotherapy to the esophagus.

             4. Has a known history of eosinophilic esophagitis or endoscopic findings suggestive
             of eosinophilic esophagitis.

             5. Has active gastric or duodenal ulcers within 4 weeks prior to Day -1. 6. Has any
             finding in his/her medical history, physical examination, or safety clinical
             laboratory tests giving reasonable suspicion of underlying disease that might
             interfere with the conduct of the trial.

             7. Has a history of hypersensitivity or allergies to dexlansoprazole or any component
             of dexlansoprazole or any proton pump inhibitor (PPI) (including lansoprazole,
             omeprazole, rabeprazole, pantoprazole, or esomeprazole) or antacid.

             8. Is required to take excluded medications or it is anticipated that the participant
             will require treatment with at least one of the disallowed concomitant medications
             during the study evaluation period as specified in the Excluded Medications and
             Treatments Section..

             9. Has a history of malignant disease (except basal cell carcinoma) within 5 years
             prior to Screening.

             10. Has a condition that may require inpatient surgery during the course of the
             study.

             11. Requires dilatation of esophageal strictures and/or strictures preventing passage
             of the endoscope during the Screening endoscopy. Schatzki's ring (a ring of mucosal
             tissue near the lower esophageal sphincter) is acceptable.

             12. Is known to have acquired immunodeficiency syndrome. 13. Has current or clinical
             history of Zollinger-Ellison syndrome or other hypersecretory condition.

             14. Has a history of gastric, duodenal or esophageal surgery except simple oversew of
             an ulcer. A history of gastric tube and/or percutaneous endoscopic gastrostomy (PEG)
             placement is allowed.

             15. Had an acute upper gastrointestinal hemorrhage within 4 weeks prior to endoscopy.

             16. Has donated or lost â‰¥300 mL blood volume, undergone plasmapheresis, or has had a
             transfusion of any blood product within 90 days prior to the first dose of study
             drug.

             17. Has a known history of alcohol abuse or illegal drug use within the past 12
             months prior to the first dose of study drug, or is unwilling to agree to abstain
             from alcohol or illegal drug use throughout the study.

             18. If female, the participant is pregnant or lactating or intending to become
             pregnant before, during or within 30 days after last dose of study medication; or
             intending to donate ova during such time period.

             19. If male, the participant intends to donate sperm during the course of this study
             or within 30 days after last dose of study drug.

             20. Is an immediate family member, study site employee, or is in a dependent
             relationship with a study site employee who is involved in the conduct of this study
             or may consent and assent under duress. Students of the institution/research facility
             who are under the supervision of, or in a subordinate role to, the investigator are
             also ineligible.

             21. In the opinion of the investigator, is unlikely to comply with the protocol
             requirements or is unsuitable for any other reason.

             22. Has been previously randomized in this study and received at least one dose of
             double blind study drug treatment.

             23. Has received any investigational compound within 30 days prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 23, 2016</lastchanged_date>
  <firstreceived_date>June 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
